新药轮番登场,减肥药物领域迎来革命性突破

肥胖症作为全球日益严峻的健康问题,给许多人带来了困扰。随着肥胖药物研发的不断进步,越来越多的新一代药物进入临床试验,并有望突破传统减重药物的极限。这些药物不仅可以大幅减轻体重,还通过不同的生物机制对身体产生独特的代谢影响。那么,这些新药到底如何改变肥胖治疗的现状?不同药物的作用机制又有何不同?今天,我们将跟随大仔一起走进今天的文章。

讲解人 · 大仔

爱丁堡大学英语教学硕士 资深英语课程设计师

原文


        
** You're on Ozempic? How quaint. **
A whole slew of next-generation obesity drugs are on the horizon, some already advanced enough in clinical trials to be looking as good as — if not better than — those already on the market.

The novel medications continue to push the upward limits of weight loss, now to almost 25 percent of body weight on average, but they also differ in their modes of action.

Obesity, after all, is not monolithic.

About 100 million adults live with obesity in just the U.S., a market massive enough for multiple medications to find a niche.

“One size will not fit all, “ said Richard DiMarchi, a chemist at Indiana University.

Ozempic functions by mimicking a single hormone called GLP-1; the drug’s mode of action is relatively simple but limited.

The second drug currently on the market, the tirzepatide found in Mounjaro and Zepbound, resembles GLP-1 in addition to another hormone called GIP, hitting receptors for both in the brain.

Even more intriguing than the top-line weight-loss numbers are metabolic changes unique to particular drugs.

Glucagon, for example, ramps up liver metabolism; drugs based on this hormone could help break down fat accumulated in the livers of patients who also have fatty-liver disease.

Meanwhile, GLP-1-based drugs appear to protect against cardiovascular disease, even independent of weight loss.

An extensive menu of obesity drugs that work via distinct biological mechanisms means that patients will have more options to try.

If they aren’t losing weight on drug A, they can move on to drug B or C.

Further down the line, experts say, they hope to have a test, such as a blood test, that can forecast how patients will fare.

带着问题听讲解

  • 如何理解 niche 这个词?
  • 根据文章,最新减肥药物的效果如何?
  • 根据文章,不同的肥胖治疗药物能给患者带来什么?

讲解


        
** 新药轮番登场,减肥药物领域迎来革命性突破 **
A whole slew of next-generation obesity drugs are on the horizon, some already advanced enough in clinical trials to be looking as good as — if not better than — those already on the market. The novel medications continue to push the upward limits of weight loss, now to almost 25 percent of body weight on average, but they also differ in their modes of action.
一系列新一代减肥药已箭在弦上,部分药物的临床试验进展已十分成熟,疗效即便不优于现有药物,也能与之持平。这类新型药物持续突破减重效果的上限,目前平均减重幅度已接近体重的 25%,且作用机制各有不同。
Obesity, after all, is not monolithic. About 100 million adults live with obesity in just the U.S., a market massive enough for multiple medications to find a niche. "One size will not fit all," said Richard DiMarchi, a chemist at Indiana University.
毕竟,肥胖并非单一病因的疾病。仅在美国,就有约 1 亿成年人受肥胖困扰——这一庞大市场足以让多款药物找到各自的细分定位。印第安纳大学化学家理查德·迪马尔奇表示:“不存在万能的肥胖治疗方案。”
Ozempic functions by mimicking a single hormone called GLP-1; the drug's mode of action is relatively simple but limited. The second drug currently on the market, the tirzepatide found in Mounjaro and Zepbound, resembles GLP-1 in addition to another hormone called GIP, hitting receptors for both in the brain.
司美格鲁肽(Ozempic)通过模拟单一激素 GLP-1(胰高血糖素样肽 - 1)发挥作用,其作用机制相对简单但存在局限性。目前市面上的第二款药物——蒙扎罗(Mounjaro)与泽邦德(Zepbound)中的含替尔泊肽(tirzepatide),除模拟 GLP-1 外,还能模拟另一种名为 GIP(葡萄糖依赖性促胰岛素多肽)的激素,双重作用于大脑中的对应受体。
Even more intriguing than the top-line weight-loss numbers are metabolic changes unique to particular drugs. Glucagon, for example, ramps up liver metabolism; drugs based on this hormone could help break down fat accumulated in the livers of patients who also have fatty-liver disease. Meanwhile, GLP-1-based drugs appear to protect against cardiovascular disease, even independent of weight loss.
比优异的减重数据更令人关注的,是特定药物带来的独特代谢变化。例如,胰高血糖素(Glucagon)可加速肝脏代谢,基于该激素研发的药物或有助于分解脂肪肝患者肝脏中堆积的脂肪。与此同时,基于 GLP-1 的药物表现出心血管保护作用,且该效果独立于减重本身。
An extensive menu of obesity drugs that work via distinct biological mechanisms means that patients will have more options to try. If they aren't losing weight on drug A, they can move on to drug B or C. Further down the line, experts say, they hope to have a test, such as a blood test, that can forecast how patients will fare.
多款作用机制迥异的肥胖治疗药物问世,意味着患者将拥有更多尝试选择。若患者使用药物 A 未能实现减重目标,可转而尝试药物 B 或 C。专家表示,未来他们有望研发出一种检测手段(如血液检测),能够预测患者对特定药物的治疗反应。

重点词汇

quaint

/kweɪnt/

adj.(观点、信仰或行为方式)奇怪的,不合逻辑的,过时的;奇特、老派而有趣的

  • 英文释义:attractive because of being unusual and especially old-fashioned
    搭配短语quaint country cottages
    例句:"What a quaint idea!" she said, laughing at him.

slew

/sluː/

n. 大量,许多

  • 相关词汇:slay
    搭配短语:a slew of sth.

obesity

/oʊˈbiː.sə.t̬i/

n. 肥胖

  • 相关词汇:obese(adj. 肥胖的)

on the horizon
即将发生

  • 相关词汇:horizon(n. 地平线)
    英文释义:likely to happen or exist soon

monolithic

/ˌmɑː.nəˈlɪθ.ɪk/

adj. 庞大而又无特色的

  • 词根词缀:mono-(单一)=single
    • 相关词汇monologue
    词根词缀:lith(石头)
    相关词汇:monolith(n. 独块的巨石;超大人造建筑)
    英文释义:too large, too regular, and unwilling or unable to be changed
    例句:The old company had a monolithic structure, where all decisions had to be approved by the top management.

niche

/nɪtʃ/

n. 缝隙市场,利基市场,细分;壁龛;合适的小环境,合适的职位

  • 例句:He has made a niche for himself as a financial advisor.
    搭配短语niche market

mimic

/ˈmɪm.ɪk/

v. 模仿

  • 例句:She was secretly mimicking the team leaders in our office.
    词性拓展:mimic(n. 善于模仿的人)
    • 例句:He is a mimic.

top-line

/ˈtɑːp.laɪn/

adj. 质量最好的,级别最高的

  • 相关搭配:top line(营业收入);bottome line(净利润)

metabolic

/met̬.əˈbɑː.lɪk/

adj. 新陈代谢的

  • 相关词汇:metabolism
    词根词缀:meta-(变化;在……之后)

ramp up
扩大,增加,提高

  • 相关词汇:ramp(n. 斜坡,辅路)
    近义词:increase
    搭配短语:to ramp up production
    例句:The news is expected to ramp up share prices.

cardiovascular
adj. 心血管的

  • 词根词缀:cardio-(和心脏有关的)
    词根词缀:vascular(血管的)

down the line
未来

  • 相关短语:down the road/track
    相关短语:in the future
    例句:Cars that drive themselves are in development now, but a marketable product is a long way down the line.

fare

/fer/

v. 进展如何,表现如何

  • 词性拓展:fare(n. 车费,车票价)
    • 例句:Train fares are going up again.
    英文释义:to get along or manage in a specified way
    例句:How did you fare on your exam?
    例句:The team fared better/worse this year.
    近义词:perform

拓展阅读

在美国,减肥药进入“以价换量”新阶段
全球减肥药市场正迎来深刻变革,以价换量和消费化趋势正在重塑行业格局。高盛 12 月 8 日报告指出,礼来与诺和诺德近期与特朗普政府达成的定价协议成为关键催化剂。自 2026 年起,Zepbound、Wegovy 等核心 GLP-1 药物价格将显著下调,并有望首次纳入美国联邦医疗保险(Medicare)覆盖范围。
与此同时,直接面向消费者(DTC)的销售渠道、零售商合作以及远程医疗平台的兴起,正共同推动减肥药市场的“消费化”浪潮。
受降价预期推动及消费化的趋势影响,高盛将其对 2030 年全球抗肥胖药物(AOM)市场的规模预测上调至约 1020 亿美元。
该协议旨在通过降低价格,扩大在美国联邦医疗保险(Medicare)、医疗补助(Medicaid)以及直接面向消费者(DTC)现金支付渠道的患者可及性。换句话说,这其实相当于将药品纳入了医保范围。
报告详细阐述了协议的关键内容,该协议自 2026 年起生效:
  1. Medicare(联邦医疗保险): 从 2026 年 4 月 1 日开始,一项试点计划将使 Zepbound 和 Wegovy 的肥胖适应症被纳入 Medicare D 部分覆盖范围,月费定价为 245 美元,患者自付费用上限为 50 美元。作为交换,用于糖尿病的 Mounjaro 和 Ozempic 价格也将降至 245 美元/月(此前高盛预估为 350 美元)。这移除了一个关键的增长限制。
  2. Medicaid(医疗补助计划): Zepbound 和 Wegovy 的 Medicaid 价格同样为每月 245 美元,但具体覆盖范围由各州决定。目前已有 13 个州完全覆盖 GLP-1 类减肥药。
  3. DTC/现金支付: 价格也更具吸引力。例如,诺和诺德的 Wegovy 价格为 349 美元(起始剂量除外);礼来的 Zepbound 多剂量笔起始价为 299 美元,后续剂量最高 449 美元;而备受期待的口服药 orforglipron 起始价仅为 149 美元,后续剂量最高 399 美元。
以上内容原载于网络,由流利说®阅读团队修改编辑。